ALSO NOTED: Endo wins patent suit; Judge rules against trial patients; Biota shares surge on discovery; and much more...

> Shares of Endo surged yesterday afternoon after the company reported it had won a patent suit allowing it to market a generic version of the extended release form of Oxycontin. Story

> A judge has ruled against two patients who tried to force Amgen to continue to supply them with an experimental Parkinson's drug. Amgen had suspended the trial after determining that GDNF was no better than a placebo and could be dangerous. The judge ruled that the biotech giant was under no contractual obligation to continue to provide the drug. Article

> Shares of Australia's Biota Holdings surged after the company announced it had found a novel class of antivirals. Story

> Nymox of Maywood, New Jersey, is reporting positive data for its experimental drug for benign prostatic hyperplasia. Release

> Tracleer is gaining a new market in Japan, where it will be sold for $60,000, well above the $35,000 price tag found in the US. Story

> Vical has licensed three cancer vaccine targets to Merck. Release

> Novavax of Malvern, Pennsylvania, has announced preclinical results for two compounds. Release

And Finally... Doctors are trying to create a "firewall" to separate them from drug company freebies, but the close ties have proved hard to unravel. Article

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.